| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5692473 | The Breast | 2017 | 7 Pages |
Abstract
Treatment with CDK 4/6 inhibitors is well tolerated and associated with a low risk of treatment-related deaths. There is an increased AR of grade 3/4 neutropenia but a low AR of associated infections.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
R. Costa, R.B. Costa, Sarah M. Talamantes, Irene Helenowski, Jonna Peterson, Jason Kaplan, B.A. Carneiro, Francis J. Giles, W.J. Gradishar,